Diabetes Mellitus adalah penyakit kronik yang disebabkan oleh faktor genetik, karena kesalahan pola makan, atau gaya hidup yang tidak sehat. Diet Diabetes dan Self management Diabetes menjadi poin penting pada tata laksana DM tipe 2. Persadia (Perhimpunan Diabetes Indonesia) adalah perkumpulan pasien dan keluarga penderita diabetes di Indonesia yang bertujuan untuk edukasi pada pasien DM tipe 2. Persadia bertujuan meningkatkan kualitas hidup penderita diabetes dan mencegah komplikasi diabetes pada pasien diabetes. Analisis situasi sebelumnya menunjukkan pasien diabetes anggota persadia cabang Surakarta mempunyai keterbatasan dalam pengetahuan tentang diet diabetes, self managemengt diabetes, dan tingkat stres dalam menjalakan diet cukup tinggi. Tujuan pengabdian ini adalah pengabdian untuk meningkatkan pengetahuan diet diabetes, self management diabetes, dan menurunkan tingkat stres pada pasien DM tipe 2 anggota persadia di RS UNS. Metode yang dilakukan adalah dengan pemberian ceramah, diskusi, dan video edukasi. Sebelum dan sesudah pengabdian dilakukan pemberian kuesioner pengetahuan diet diabetes, kuesioner self management diabetes, dan kuesioner tingkat stres dalam menjalankan diet. Hasil pengabdian menunjukkan peningkatan pengetahuan diet diabetes (rerata peningkatan skor pengetahuan diet diabetes adalah 24,5+6,2), self management diabetes (rerata peningkatan skor self management diabetes 8,2+ 4,34), dan penurunan tingkat stres (rerata penurunan skor 14,5+5,32) pada pasien DM tipe 2 anggota persadia di RS UNS. Secara tidak langsung kegiatan pengabdian kepada masyarakat ini akan meningkatkan kualitas hidup dan kesejahteraan pada pasien DM tipe 2 dalam lingkungan persadia RS UNS.
N-acetylcysteine has antioxidant and anti-inflammatory activities that could potentially improve the clinical outcomes of coronavirus disease 2019 (COVID-19) patients. N-acetylcysteine potentially inhibits NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome and results in control oxidative stress and cytokine release in COVID-19 patients. The aim of this study was to assess the effect of N-acetylcysteine in reducing the neutrophil-lymphocyte ratio (NLR) in COVID-19 patients. A randomized controlled clinical trial was conducted among severe and moderate COVID-19 patients. The treatment group received oral 1200 mg daily of N-acetylcysteine (three times a day) and the standard care for COVID-19, while the control group received standard care for COVID-19 and a placebo. The NLR was determined on the first day of admission and after the seventh day of treatment. A paired Student t-test was used to compare the NLR before and after treatment while independent Student t-test was used to compare the NLR between treatment and control groups. A total of 40 severe and moderate COVID-19 were enrolled, 20 people in each group, with a mean age was 44.68±13.24 years old. The mean NLR on the first day was 9.44 in the treatment group and 8.84 in the control group. After the seventh day, the mean NLR was 4.27 and 11.54 in the treatment group and control group, respectively. The mean changes of NLR (the pre-treatment compared to post-treatment) in the treatment and control group were reduced 4.05 and increased 3.34, respectively. The NLR in treatment group significantly decreased compared to the control group (p<0.001). In conclusion, N-acetylcysteine 1200 mg daily could reduce the NLR in severe and moderate COVID-19 patients.
1 February 2021 in Bangladesh Journal of Medical Science
Background: Systemic lupus erythematosus is a chronic autoimmune disease that affects target organs. mesenchymal stem cell conditioned medium has immunosuppressive, anti-inflammatory, and immunoregulatory properties in lupus. Methyl prednisolone is a standard drug for lupus with immunosuppressive and anti-inflammatory properties. This study aims to compare the therapeutic effect of mesenchymal stem cell conditioned medium administration compared to methyl prednisolone on interleukin 10 levels and the degree of pulmonary vasculitis of lupus mice. Methods: The subjects were 24 female mice of Mus musculus Balb/C strain, which were categorized into 4 groups of 8 mice, i.e. the control group receiving 0.5 cc of 0.9% NaCl injection and placebo, the lupus group receiving 0.5 cc of pristane injection and placebo, and the treatment mesenchymal stem cell conditioned medium group receiving 0.5 cc pristane injection and mesenchymal stem cell conditioned medium 0,5 cc, and methylprednisolone group receiving 0,5 cc pristiane injection and methylprednisolone p.o 1,5 mg/kgbodyweight. After 24 days the mice were terminated and kidney and blood samples were taken. Statistical analysis was performed using ANOVA test followed by independent T-test. The p value was considered significant when the p < 0.05. Results: The study showed that there was no difference on the levels of interleukin level10 among mesenchymal stem cell conditioned medium goup and methyl prednisolone group (CM = 5,94 ± 2,49 pg/mL, mp = 5,86+1,73 pg/mL; p = 1) and the degree of pulmonary vasculitis (CM= 1,94 ± 0,25, MP=1,89+ 0,11 pg/ml; p = 0.667). Mesenchymal stem cell conditioned medium as good as methyl prednisolone in decreasing levels of interleukin 10 and the degree of pulmonary vasculitis in lupus mice. Conclusion: Mesenchymal stem cell conditioned medium as good as methyl prednisolone in decreasing levels of interleukin 10 and the degree of pulmonary vasculitis in lupus mice Bangladesh Journal of Medical Science Vol.20(2) 2021 p.426-430
1 January 2021 in Bangladesh Journal of Medical Science
Introduction: No definitive treatment is available for Lupus. Moringaoleiferais one of promisingnovel treatments in Lupus trough anti inflammation and immunosupresion. Mean platelet volume andneutrophil to lymphocyte ratio used to measure degree of lupus activities. Objective: Our study wasaimed to identify the effect of Moringaoleiferaextract on the Mean platelet volume and neutrophil to lymphocyte ratio in lupus. Methods: This experimental study was conducted in 30 lupus patients,located in the rheumatology clinic at Moewardi General Hospital in January-March 2019. The studygroup was divided into two groups: the treatment research group received 2 grams of moringa extractper day and the placebo group. The study was conducted for 4 weeks and was evaluated when thestudy was completed. MPV and NLR examination using a hemocytometer. Statistical analysis wasperformed using paired T test, independent T-test. The p value was considered significant when the p < 0.05. Results: The results showed a decrease in MPV (delta MPV = 4.141; r 0.656; p-0.02) anda decrease in Neurophil to lymfocyte ratio (delta NLR = 4.1391; r 0.489; p-0.04) Conclusion: Thestudy demonstrated the effect of Moringaoleiferaleaf extract on reduced Mean platelet volume andneutrophil to lymphocyte ratio in lupus Bangladesh Journal of Medical Science Vol.20(1) 2021 p.68-73
11 April 2023 in Bangladesh Journal of Medical Science
Moringa oleifera (MO) has anti-inflammatory, anti-arthritis, and immunosuppressant effects in Rheumatoid Arthritis (RA). This study aims to determine the effect of moringa oleifera extract on interleukin 6 levels and disease activity in RA. This research, with 30 patients, was divided into two groups: the intervention and the placebo. The intervention group received 40.50 mg/kg BW/day of Moringa oleifera extract for one month. IL-6 levels and SDAI scores were measured before and after the treatment. Paired t-test showed that IL-6 levels (p=0.070) and SDAI Scores (p=0.142) before and after MO administration for the control group were not significantly different (p> 0.05). Paired t-test IL-6 (p=0.001) and SDAI Scores (p=0.001) before and after giving MO to the treatment group decreased significantly (p <0.05). Independent t-test shows that the two changes, Delta-IL6 (p=0,008) and Delta-SDAI (p=0,017), are significantly different (p<0.05). Moringa Oleifera Extract decreases IL-6 Levels and SDAI Scores in RA Patients. Bangladesh Journal of Medical Science Vol. 22 No. 02 April’23 Page : 416-421
1 July 2021 in IOP Conference Series: Earth and Environmental Science
COVID-19 increases vulnerability for populations living in regions significantly impacted by the adverse effects of climate change. There is currently no definitive treatment for COVID-19. Colchicine is a drug that can reduce the severity of COVID-19 by inhibiting the NLRP3 inflammasome. This study aims to determine the effect of colchicine administration on the high-sensitivity C-reactive protein (HsCRP) and Neutrophil to Lymphocyte Ratio (NLR) levels in COVID-19 patients. This study was conducted at the UNS Hospital in February-March 2021. The inclusion criteria were moderate-grade COVID-19 patients. HsCRP and NLR examinations were carried out before and after giving the treatment. The treatment group received 2x0.5 mg colchicine for 7 days and standard therapy, while the control group received placebo and standard therapy. Statistical test using paired t-test and independent t-test. P is significant if p is less than 0.05. The study subjects were 40 patients, with 20 patients in the control group and 20 in the treatment group. There was a decrease in NLR and HsCRP levels in the treatment group before therapy (NLR = 7.89 + 3.45; HsCRP = 5.41 + 3.24 mg/dL) compared to after therapy (NLR = 3.59 + 2.25; HsCRP = 1.41 + 1.13 mg/dL) with p = 0.001. Colchicine reduces the degree of NLR and HsCRP in COVID-19 patients.